Key takeaways for Delaware
- • No GLP-1 is FDA-approved for PCOS — entirely off-label.
- • BMI 27+ may qualify under standard Wegovy/Zepbound labels if comorbidities present.
- • Improvements seen in insulin resistance, weight, and androgens; fertility data limited.
- • Delaware Medicaid coverage rules apply for PCOS (Polycystic Ovary Syndrome) patients in Delaware — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for PCOS (Polycystic Ovary Syndrome)
No GLP-1 is FDA-approved specifically for PCOS. However, small randomized trials and observational studies show GLP-1 RAs improve insulin sensitivity, support 5-15% weight loss, reduce free testosterone, and may improve menstrual regularity and ovulation. Evidence grade: C-B (smaller trials, growing evidence base). PCOS guidelines (ESHRE/Monash 2023) recognize obesity-targeted pharmacotherapy as adjunct. Patients trying to conceive should stop GLP-1s at least 2 months before pregnancy attempts.
Delaware-specific context
Delaware has telehealth access concentrated in Wilmington, Dover, Newark metros, with additional reach to Middletown and Smyrna. ChristianaCare is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.dhss.delaware.gov.
Delawaretelehealth & pricing rules
- • Delaware permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Delaware allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Delaware: ~$269/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.